ArticleCancer immunology, immunotherapy : CII2026
Rituximab for severe immune checkpoint inhibitor-related adverse events: a multicenter case series.
Stéphanie Hermabessiere et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
this papercites it